63762-83-4

Usage

Uses

Used in Pharmaceutical Research:
6-fluoro-5-methoxy-1H-indole is used as a serotonin receptor agonist for exploring its potential in treating various disorders associated with serotonin dysregulation. Its unique structure allows for specific interactions with serotonin receptors, which can be leveraged to develop new therapeutic agents.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 6-fluoro-5-methoxy-1H-indole is used to investigate its potential as an antimicrobial agent. 6-fluoro-5-methoxy-1H-indole's ability to interfere with microbial processes makes it a candidate for developing new antibiotics or antifungal drugs, contributing to the fight against drug-resistant infections.
Used in Anticancer Research:
6-fluoro-5-methoxy-1H-indole is employed in oncology research as a compound with potential anticancer properties. Studies are conducted to understand its effects on cancer cells and its potential to be developed into a chemotherapeutic agent, especially given its unique molecular structure that may allow for selective targeting of cancerous cells.
Used in Organic Synthesis:
As a building block in organic synthesis, 6-fluoro-5-methoxy-1H-indole is used for the creation of more complex organic compounds. Its versatile structure makes it a valuable precursor in the synthesis of a variety of molecules, including those with potential applications in material science, pharmaceuticals, and other chemical industries.
Used in Chemical Research:
In the broader field of chemical research, 6-fluoro-5-methoxy-1H-indole serves as a subject for studying the effects of fluorination and methoxylation on indole's chemical behavior. Understanding these effects can provide insights into the design of new molecules with tailored properties for specific applications.

InChI:InChI=1/C9H8FNO/c1-12-9-4-6-2-3-11-8(6)5-7(9)10/h2-5,11H,1H3

Upstream product

• 455-93-6 2-fluoro-1-methoxy-4-nitrobenzene 
• 64-17-5 ethanol 
• 947380-12-3 (4-fluoro-5-methoxy-2-nitro-phenyl)-acetonitrile 

Downstream Products

• 1415346-00-7 6-fluoro-5-methoxy-1-phenyl-1H-indole 
• 1415346-01-8 6-fluoro-1-phenyl-1H-indol-5-ol 
• 1415346-02-9 6-fluoro-1-phenyl-1H-indol-5-yl trifluoromethanesulfonate 
• 1415346-03-0 N-(2-(tert-butyldimethylsilyloxy)ethyl)-6-fluoro-1-phenyl-1H-indol-5-amine 
• 1415346-04-1 N-(2-(tert-butyldimethylsilyloxy)ethyl)-4,6-dichloro-N-(6-fluoro-1-phenyl-1H-indol-5-yl)pyrimidine-5-carboxamide 
• 1415346-05-2 4,6-dichloro-N-(6-fluoro-1-phenyl-1H-indol-5-yl)-N-(2-hydroxyethyl)pyrimidine-5-carboxamide 
• 1415346-06-3 4-chloro-6-(6-fluoro-1-phenyl-1H-indol-5-yl)-7,8-dihydrooxazepino[2,3-d]pyrimidin-5(6H)-one 
• 1415345-12-8 4-amino-6-(6-fluoro-1-phenyl-1H-indol-5-yl)-7,8-dihydrooxazepino[2,3-d]pyrimidin-5(6H)-one 

Relevant academic research and scientific papers

N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR

The present invention relates to the use compounds of formula I which are antagonists of the 5-HT 6 receptor, for treating a cognitive disorder selected from the group consisting of age-related cognitive decline, mild cognitive impairment and dementia

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

TETRACYCLIC INDOLOPYRIDINES AS EG5 INHIBITORS

Compounds of a certain formula (I), in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.

INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 )

Compounds of formula (I), in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.

(AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, -N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

INDOLOPYRIDINES AS EG5 KINESIN MODULATORS

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Quinoline derivatives having vegf inhibiting activity

The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4; n is an integer from 0 to 5; m is an integer from 0 to 3; Ra represents hydrogen or fluoro; Rb, R1 and R2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

Cinnoline compounds

The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3aklylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Chemical compounds

The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S, and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—; or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, NH—, —S—, CH2— or a direct substituents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, hydroxy, halogeno, C1-4alkyl, or any other value as defined herein; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions

Synthesis and evaluation of the antiovulatory activity of a variety of melatonin analogues

A series of melatonin analogues was synthesized and examined for ovulation-blocking activity. Deviation from the 5-methoxy group or substitution of the 1 position prevented activity. Activity was not particularly sensitive to minor variations in the N-acyl group nor was it significantly altered by methylation of position 2 or the α-methylene; however, a pronounced enhancement resulted from halogenation of the 6 position.